Biotech News

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

Cytokinetics (CYTK)Cytokinetics2026-11-02 12:30 ESTPartnership

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions, taking place in Chicago, IL, November 6, 2026.

Cytokinetics

Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin...

Recent company news

CYTKCytokinetics2026-11-03 21:00 EST

Cytokinetics to Participate in November Investor Conferences

CYTKCytokinetics2026-11-02 12:30 EST